{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:20:07Z","timestamp":1793024407668,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"DOI":"10.7759\/cureus.100993","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:16:26Z","timestamp":1767791786000},"source":"Crossref","is-referenced-by-count":5,"title":["The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management"],"prefix":"10.7759","author":[{"given":"Amaan","family":"Alvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hithyshi","family":"Singamala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Surya Vamsi","family":"Gadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya Kumar","family":"Javvaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami J","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JE, et al.. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019, 139:e840-78. 10.1161\/CIR.0000000000000664","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.01.011","article-title":"Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance","volume":"10","author":"Metra M","year":"2008","unstructured":"Metra M, Nodari S, Parrinello G, et al.. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008, 10:188-95. 10.1016\/j.ejheart.2008.01.011","journal-title":"Eur J Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.01.077","article-title":"Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure","volume":"60","author":"Ronco C","year":"2012","unstructured":"Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol. 2012, 60:1031-42. 10.1016\/j.jacc.2012.01.077","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-015-0254-8","article-title":"Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect?","volume":"12","author":"Colombo PC","year":"2015","unstructured":"Colombo PC, Doran AC, Onat D, Wong KY, Ahmad M, Sabbah HN, Demmer RT. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect?. Curr Heart Fail Rep. 2015, 12:215-22. 10.1007\/s11897-015-0254-8","journal-title":"Curr Heart Fail Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1440241","article-title":"The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure","volume":"15","author":"Jarmukhanov Z","year":"2024","unstructured":"Jarmukhanov Z, Mukhanbetzhanov N, Kozhakhmetov S, Nurgaziyev M, Sailybayeva A, Bekbossynova M, Kushugulova A. The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure. Front Microbiol. 2024, 15:1440241. 10.3389\/fmicb.2024.1440241","journal-title":"Front Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00895-8","article-title":"Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis","volume":"30","author":"Jang JW","year":"2024","unstructured":"Jang JW, Capaldi E, Smith T, Verma P, Varga J, Ho KJ. Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis. Mol Med. 2024, 30:128. 10.1186\/s10020-024-00895-8","journal-title":"Mol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood JT","year":"2007","unstructured":"Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007, 13:422-30. 10.1016\/j.cardfail.2007.03.011","journal-title":"J Card Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita K","year":"2015","unstructured":"Matsushita K, Coresh J, Sang Y, et al.. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015, 3:514-25. 10.1016\/S2213-8587(15)00040-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2022.06.015","article-title":"Acute kidney injury patterns in acute heart failure: the prognostic value of worsening renal function and its timing","volume":"42","author":"Presume J","year":"2023","unstructured":"Presume J, Cunha GJ, Rocha BM, et al.. Acute kidney injury patterns in acute heart failure: the prognostic value of worsening renal function and its timing. Rev Port Cardiol. 2023, 42:423-30. 10.1016\/j.repc.2022.06.015","journal-title":"Rev Port Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00728-8","article-title":"Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the Global Burden of Disease Study 2021","volume":"13","author":"Ran J","year":"2025","unstructured":"Ran J, Zhou P, Wang J, et al.. Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the Global Burden of Disease Study 2021. Biomark Res. 2025, 13:16. 10.1186\/s40364-025-00728-8","journal-title":"Biomark Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080831","article-title":"\u03b2-blockers in dialysis patients: a nephrocardiology perspective","volume":"26","author":"Shroff GR","year":"2015","unstructured":"Shroff GR, Herzog CA. \u03b2-blockers in dialysis patients: a nephrocardiology perspective. J Am Soc Nephrol. 2015, 26:774-6. 10.1681\/ASN.2014080831","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.392","article-title":"Effects of sacubitril\/valsartan across the spectrum of renal impairment in patients with heart failure","volume":"83","author":"Chatur S","year":"2024","unstructured":"Chatur S, Neuen BL, Claggett BL, et al.. Effects of sacubitril\/valsartan across the spectrum of renal impairment in patients with heart failure. J Am Coll Cardiol. 2024, 83:2148-59. 10.1016\/j.jacc.2024.03.392","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02919-z","article-title":"Cardio-renal benefits of sacubitril\/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice","volume":"23","author":"Mart\u00ednez-Esteban MD","year":"2022","unstructured":"Mart\u00ednez-Esteban MD, V\u00e1zquez-S\u00e1nchez T, Pozo-\u00c1lvarez R, et al.. Cardio-renal benefits of sacubitril\/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice. BMC Nephrol. 2022, 23:293. 10.1186\/s12882-022-02919-z","journal-title":"BMC Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000450526","article-title":"Assessment and management of volume overload and congestion in chronic heart failure: can measuring blood volume provide new insights","volume":"2","author":"Miller WL","year":"2017","unstructured":"Miller WL. Assessment and management of volume overload and congestion in chronic heart failure: can measuring blood volume provide new insights. Kidney Dis (Basel). 2017, 2:164-9. 10.1159\/000450526","journal-title":"Kidney Dis (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma EM","year":"2020","unstructured":"Boorsma EM, Ter Maaten JM, Damman K, et al.. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020, 17:641-55. 10.1038\/s41569-020-0379-7","journal-title":"Nat Rev Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad169","article-title":"Multidisciplinary approach to patients with heart failure and kidney disease: preliminary experience of an integrated cardiorenal unit","volume":"16","author":"Marques M","year":"2023","unstructured":"Marques M, Cobo M, L\u00f3pez-S\u00e1nchez P, et al.. Multidisciplinary approach to patients with heart failure and kidney disease: preliminary experience of an integrated cardiorenal unit. Clin Kidney J. 2023, 16:2100-7. 10.1093\/ckj\/sfad169","journal-title":"Clin Kidney J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100109","article-title":"Advancements and applications of artificial intelligence in cardiology: current trends and future prospects","volume":"3","author":"Olawade DB","year":"2024","unstructured":"Olawade DB, Aderinto N, Olatunji G, Kokori E, Aanuoluwapo CDC, Hadi M. Advancements and applications of artificial intelligence in cardiology: current trends and future prospects. J Med Surg Public Health. 2024, 3:100109. 10.1016\/j.glmedi.2024.100109","journal-title":"J Med Surg Public Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1236177","article-title":"Measured sodium excretion is associated with cardiovascular outcomes in non-dialysis CKD patients: results from the KNOW-CKD study","volume":"3","author":"Kang SC","year":"2023","unstructured":"Kang SC, Kang M, Ryu H, et al.. Measured sodium excretion is associated with cardiovascular outcomes in non-dialysis CKD patients: results from the KNOW-CKD study. Front Nephrol. 2023, 3:1236177. 10.3389\/fneph.2023.1236177","journal-title":"Front Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16371","article-title":"The interplay between heart failure and chronic kidney disease","volume":"27","author":"Lala A","year":"2025","unstructured":"Lala A, Levin A, Khunti K. The interplay between heart failure and chronic kidney disease. Diabetes Obes Metab. 2025, 27:3568-82. 10.1111\/dom.16371","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens W","year":"2009","unstructured":"Mullens W, Abrahams Z, Francis GS, et al.. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009, 53:589-96. 10.1016\/j.jacc.2008.05.068","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.406","article-title":"The relevance of congestion in the cardio-renal syndrome","volume":"83","author":"F Gnanaraj J","year":"2013","unstructured":"F Gnanaraj J, von Haehling S, Anker SD, Raj DS, Radhakrishnan J. The relevance of congestion in the cardio-renal syndrome. Kidney Int. 2013, 83:384-91. 10.1038\/ki.2012.406","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger RH","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021, 11:263-76. 10.21037\/cdt-20-302","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2002.007005","article-title":"Inflammatory mediators in chronic heart failure: an overview","volume":"90","author":"Anker SD","year":"2004","unstructured":"Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004, 90:464-70. 10.1136\/hrt.2002.007005","journal-title":"Heart"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017121334","article-title":"Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis","volume":"29","author":"Marthi A","year":"2018","unstructured":"Marthi A, Donovan K, Haynes R, et al.. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J Am Soc Nephrol. 2018, 29:2015-27. 10.1681\/ASN.2017121334","journal-title":"J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002206","article-title":"Gut microbiota and microbiota-derived metabolites in cardiovascular diseases","volume":"136","author":"Chen X","year":"2023","unstructured":"Chen X, Zhang H, Ren S, et al.. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases. Chin Med J (Engl). 2023, 136:2269-84. 10.1097\/CM9.0000000000002206","journal-title":"Chin Med J (Engl)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2020.12.001","article-title":"Anemia of cardiorenal syndrome","volume":"11","author":"McCullough PA","year":"2021","unstructured":"McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl (2011). 2021, 11:35-45. 10.1016\/j.kisu.2020.12.001","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2018.08.004","article-title":"Cardiorenal syndrome: an overview","volume":"25","author":"Ronco C","year":"2018","unstructured":"Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018, 25:382-90. 10.1053\/j.ackd.2018.08.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.01.005","article-title":"Pathophysiology of the cardio-renal syndromes types 1-5: an uptodate","volume":"69","author":"Di Lullo L","year":"2017","unstructured":"Di Lullo L, Bellasi A, Barbera V, et al.. Pathophysiology of the cardio-renal syndromes types 1-5: an uptodate. Indian Heart J. 2017, 69:255-65. 10.1016\/j.ihj.2017.01.005","journal-title":"Indian Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2021.0039","article-title":"Prognostic and therapeutic implications of renal insufficiency in heart failure","volume":"4","author":"Jang SY","year":"2022","unstructured":"Jang SY, Yang DH. Prognostic and therapeutic implications of renal insufficiency in heart failure. Int J Heart Fail. 2022, 4:75-90. 10.36628\/ijhf.2021.0039","journal-title":"Int J Heart Fail"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman K","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014, 35:455-69. 10.1093\/eurheartj\/eht386","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-012-9317-z","article-title":"Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations","volume":"18","author":"Brandimarte F","year":"2013","unstructured":"Brandimarte F, Vaduganathan M, Mureddu GF, et al.. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations. Heart Fail Rev. 2013, 18:167-76. 10.1007\/s10741-012-9317-z","journal-title":"Heart Fail Rev"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","article-title":"Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula","volume":"5","author":"McAlister FA","year":"2012","unstructured":"McAlister FA, Ezekowitz J, Tarantini L, et al.. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail. 2012, 5:309-14. 10.1161\/CIRCHEARTFAILURE.111.966242","journal-title":"Circ Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: an update","volume":"36","author":"Damman K","year":"2015","unstructured":"Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015, 36:1437-44. 10.1093\/eurheartj\/ehv010","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-022-01208-x","article-title":"Heart failure-type symptom scores in chronic kidney disease: the importance of body mass index","volume":"46","author":"Walther CP","year":"2022","unstructured":"Walther CP, Benoit JS, Gregg LP, et al.. Heart failure-type symptom scores in chronic kidney disease: the importance of body mass index. Int J Obes (Lond). 2022, 46:1910-7. 10.1038\/s41366-022-01208-x","journal-title":"Int J Obes (Lond)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.07.014","article-title":"State of the art: using natriuretic peptide levels in clinical practice","volume":"10","author":"Maisel A","year":"2008","unstructured":"Maisel A, Mueller C, Adams K Jr, et al.. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008, 10:824-39. 10.1016\/j.ejheart.2008.07.014","journal-title":"Eur J Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51672","article-title":"Cardiac magnetic resonance imaging findings in patients with chronic kidney disease and end-stage kidney disease: a systematic review and meta-analysis","volume":"16","author":"Chandramohan D","year":"2024","unstructured":"Chandramohan D, Rajasekaran R, Konda R, et al.. Cardiac magnetic resonance imaging findings in patients with chronic kidney disease and end-stage kidney disease: a systematic review and meta-analysis. Cureus. 2024, 16:e51672. 10.7759\/cureus.51672","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.08.021","article-title":"IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays","volume":"48","author":"Apple FS","year":"2015","unstructured":"Apple FS, Jaffe AS, Collinson P, et al.. IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin Biochem. 2015, 48:201-3. 10.1016\/j.clinbiochem.2014.08.021","journal-title":"Clin Biochem"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14202316","article-title":"Cardiac troponin levels in patients with chronic kidney disease: \u201cmarkers of high risk or just noise\u2019\u2019?","volume":"14","author":"Geladari EV","year":"2024","unstructured":"Geladari EV, Vallianou NG, Evangelopoulos A, et al.. Cardiac troponin levels in patients with chronic kidney disease: \u201cmarkers of high risk or just noise\u2019\u2019?. Diagnostics (Basel). 2024, 14:2316. 10.3390\/diagnostics14202316","journal-title":"Diagnostics (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013357","article-title":"Association between high-sensitivity cardiac troponin T and echocardiographic parameters in chronic kidney disease: results from the KNOW-CKD cohort study","volume":"8","author":"Kang E","year":"2019","unstructured":"Kang E, Ryu H, Kim J, et al.. Association between high-sensitivity cardiac troponin T and echocardiographic parameters in chronic kidney disease: results from the KNOW-CKD cohort study. J Am Heart Assoc. 2019, 8:e013357. 10.1161\/JAHA.119.013357","journal-title":"J Am Heart Assoc"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.306621","article-title":"Educational recommendations on selected analytical and clinical aspects of natriuretic peptides with a focus on heart failure: a report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers","volume":"65","author":"Kavsak PA","year":"2019","unstructured":"Kavsak PA, Lam CS, Saenger AK, et al.. Educational recommendations on selected analytical and clinical aspects of natriuretic peptides with a focus on heart failure: a report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Clin Chem. 2019, 65:1221-7. 10.1373\/clinchem.2019.306621","journal-title":"Clin Chem"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17799-4","article-title":"Prognostic values of high sensitivity cardiac troponin T and I for long-term mortality in hemodialysis patients","volume":"12","author":"Noppakun K","year":"2022","unstructured":"Noppakun K, Ratnachina K, Osataphan N, Phrommintikul A, Wongcharoen W. Prognostic values of high sensitivity cardiac troponin T and I for long-term mortality in hemodialysis patients. Sci Rep. 2022, 12:13929. 10.1038\/s41598-022-17799-4","journal-title":"Sci Rep"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2021.0036","article-title":"Fourth universal definition of myocardial infarction. Selected messages from the European Society of Cardiology document and lessons learned from the new guidelines on ST-segment elevation myocardial infarction and non-ST-segment elevation-acute coronary syndrome","volume":"28","author":"Domienik-Kar\u0142owicz J","year":"2021","unstructured":"Domienik-Kar\u0142owicz J, Kupczy\u0144ska K, Michalski B, et al.. Fourth universal definition of myocardial infarction. Selected messages from the European Society of Cardiology document and lessons learned from the new guidelines on ST-segment elevation myocardial infarction and non-ST-segment elevation-acute coronary syndrome. Cardiol J. 2021, 28:195-201. 10.5603\/CJ.a2021.0036","journal-title":"Cardiol J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/echo.13495","article-title":"Echocardiographic assessment in patients with chronic kidney disease: current update","volume":"34","author":"Sulemane S","year":"2017","unstructured":"Sulemane S, Panoulas VF, Nihoyannopoulos P. Echocardiographic assessment in patients with chronic kidney disease: current update. Echocardiography. 2017, 34:594-602. 10.1111\/echo.13495","journal-title":"Echocardiography"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2947","article-title":"Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction","volume":"25","author":"Brann A","year":"2023","unstructured":"Brann A, Miller J, Eshraghian E, Park JJ, Greenberg B. Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2023, 25:1755-65. 10.1002\/ejhf.2947","journal-title":"Eur J Heart Fail"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100705","article-title":"Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder","volume":"5","author":"Patel RN","year":"2023","unstructured":"Patel RN, Sharma A, Prasad A, Bansal S. Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder. Kidney Med. 2023, 5:100705. 10.1016\/j.xkme.2023.100705","journal-title":"Kidney Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12030161","article-title":"Cardiac remodeling in chronic kidney disease","volume":"12","author":"Kaesler N","year":"2020","unstructured":"Kaesler N, Babler A, Floege J, Kramann R. Cardiac remodeling in chronic kidney disease. Toxins (Basel). 2020, 12:161. 10.3390\/toxins12030161","journal-title":"Toxins (Basel)"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-18-S1-P241","article-title":"Non-contrast cardiac MRI for tissue characterization in patients with end stage renal disease","volume":"18","author":"Stromp TA","year":"2016","unstructured":"Stromp TA, Kaine JC, Andres KN, et al.. Non-contrast cardiac MRI for tissue characterization in patients with end stage renal disease. J Cardiovasc Magn Reson. 2016, 18:P241. 10.1186\/1532-429X-18-S1-P241","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2013.09.025","article-title":"Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance","volume":"7","author":"Edwards NC","year":"2014","unstructured":"Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2014, 7:703-14. 10.1016\/j.jcmg.2013.09.025","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-21-7680","article-title":"Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use","volume":"49","author":"Cheong BY","year":"2022","unstructured":"Cheong BY, Wilson JM, Preventza OA, Muthupillai R. Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use. Tex Heart Inst J. 2022, 49:e217680. 10.14503\/THIJ-21-7680","journal-title":"Tex Heart Inst J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s12410-018-9441-9","article-title":"Characterizing cardiac involvement in chronic kidney disease using CMR\u2014a systematic review","volume":"11","author":"Mangion K","year":"2018","unstructured":"Mangion K, McDowell K, Mark PB, Rutherford E. Characterizing cardiac involvement in chronic kidney disease using CMR\u2014a systematic review. Curr Cardiovasc Imaging Rep. 2018, 11:2. 10.1007\/s12410-018-9441-9","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000532","article-title":"Acute cardiorenal syndrome: an update","volume":"32","author":"Sohal S","year":"2024","unstructured":"Sohal S, Uppal D, Mathai SV, Wats K, Uppal NN. Acute cardiorenal syndrome: an update. Cardiol Rev. 2024, 32:489-98. 10.1097\/CRD.0000000000000532","journal-title":"Cardiol Rev"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1098553","article-title":"How to interpret serum creatinine increases during decongestion","volume":"9","author":"Ch\u00e1vez-\u00cd\u00f1iguez JS","year":"2022","unstructured":"Ch\u00e1vez-\u00cd\u00f1iguez JS, Ivey-Miranda JB, De la Vega-Mendez FM, Borges-Vela JA. How to interpret serum creatinine increases during decongestion. Front Cardiovasc Med. 2022, 9:1098553. 10.3389\/fcvm.2022.1098553","journal-title":"Front Cardiovasc Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman K","year":"2007","unstructured":"Damman K, Navis G, Voors AA, et al.. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007, 13:599-608. 10.1016\/j.cardfail.2007.04.008","journal-title":"J Card Fail"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.06.423","article-title":"Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial","volume":"22","author":"Brisco MA","year":"2016","unstructured":"Brisco MA, Zile MR, Hanberg JS, et al.. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J Card Fail. 2016, 22:753-60. 10.1016\/j.cardfail.2016.06.423","journal-title":"J Card Fail"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2011.41.10.565","article-title":"Renal dysfunction in acute heart failure","volume":"41","author":"Han SW","year":"2011","unstructured":"Han SW, Ryu KH. Renal dysfunction in acute heart failure. Korean Circ J. 2011, 41:565-74. 10.4070\/kcj.2011.41.10.565","journal-title":"Korean Circ J"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.09.013","article-title":"Soluble ST2 and galectin-3 and progression of CKD","volume":"4","author":"Alam ML","year":"2019","unstructured":"Alam ML, Katz R, Bellovich KA, et al.. Soluble ST2 and galectin-3 and progression of CKD. Kidney Int Rep. 2019, 4:103-11. 10.1016\/j.ekir.2018.09.013","journal-title":"Kidney Int Rep"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.06.007","article-title":"Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement","volume":"33","author":"Pronschinske KB","year":"2014","unstructured":"Pronschinske KB, Qiu S, Wu C, et al.. Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement. J Heart Lung Transplant. 2014, 33:1215-22. 10.1016\/j.healun.2014.06.007","journal-title":"J Heart Lung Transplant"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100765","article-title":"Renal biomarkers in heart failure: systematic review and meta-analysis","volume":"3","author":"Kumar A","year":"2024","unstructured":"Kumar A, Chidambaram V, Geetha HS, et al.. Renal biomarkers in heart failure: systematic review and meta-analysis. JACC Adv. 2024, 3:100765. 10.1016\/j.jacadv.2023.100765","journal-title":"JACC Adv"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2020_050","article-title":"Novel biomarkers for prediction of acute kidney injury in acute heart failure","volume":"121","author":"Dankova M","year":"2020","unstructured":"Dankova M, Minarikova Z, Danko J, Gergel J, Pontuch P, Goncalvesova E. Novel biomarkers for prediction of acute kidney injury in acute heart failure. Bratisl Lek Listy. 2020, 121:321-4. 10.4149\/BLL_2020_050","journal-title":"Bratisl Lek Listy"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2011.31.2.72","article-title":"New biomarkers of acute kidney injury and the cardio-renal syndrome","volume":"31","author":"Hawkins R","year":"2011","unstructured":"Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med. 2011, 31:72-80. 10.3343\/kjlm.2011.31.2.72","journal-title":"Korean J Lab Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak MG","year":"2013","unstructured":"Shlipak MG, Matsushita K, \u00c4rnl\u00f6v J, et al.. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013, 369:932-43. 10.1056\/NEJMoa1214234","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/life15050786","article-title":"Multifactorial risk stratification in patients with heart failure, chronic kidney disease, and atrial fibrillation: a comprehensive analysis","volume":"15","author":"Iacob MS","year":"2025","unstructured":"Iacob MS, Kundnani NR, Sharma A, et al.. Multifactorial risk stratification in patients with heart failure, chronic kidney disease, and atrial fibrillation: a comprehensive analysis. Life (Basel). 2025, 15:786. 10.3390\/life15050786","journal-title":"Life (Basel)"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080734","article-title":"Cardiorenal syndrome: emerging role of medical imaging for clinical diagnosis and management","volume":"11","author":"Lin L","year":"2021","unstructured":"Lin L, Zhou X, Dekkers IA, Lamb HJ. Cardiorenal syndrome: emerging role of medical imaging for clinical diagnosis and management. J Pers Med. 2021, 11:734. 10.3390\/jpm11080734","journal-title":"J Pers Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2021.33","article-title":"Management of heart failure in patients with chronic kidney disease","volume":"17","author":"Ryan DK","year":"2022","unstructured":"Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. Eur Cardiol. 2022, 17:e17. 10.15420\/ecr.2021.33","journal-title":"Eur Cardiol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)","volume":"70","author":"Ljungman S","year":"1992","unstructured":"Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992, 70:479-87. 10.1016\/0002-9149(92)91194-9","journal-title":"Am J Cardiol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The Consensus Trial Study Group","year":"1987","unstructured":"The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316:1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1101068","article-title":"Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review","volume":"14","author":"Alshahrani S","year":"2023","unstructured":"Alshahrani S. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. Front Pharmacol. 2023, 14:1101068. 10.3389\/fphar.2023.1101068","journal-title":"Front Pharmacol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial","volume":"8","author":"Mann DL","year":"2020","unstructured":"Mann DL, Greene SJ, Givertz MM, et al.. Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial. JACC Heart Fail. 2020, 8:789-99. 10.1016\/j.jchf.2020.05.005","journal-title":"JACC Heart Fail"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer M","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, et al.. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001, 344:1651-8. 10.1056\/NEJM200105313442201","journal-title":"N Engl J Med"},{"key":"ref77","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999, 353:9-13.","journal-title":"Lancet"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson A","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, et al.. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000, 283:1295-302. 10.1001\/jama.283.10.1295","journal-title":"JAMA"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.09.037","article-title":"\u03b2-blocker prevents sudden cardiac death in patients with hemodialysis","volume":"165","author":"Matsue Y","year":"2013","unstructured":"Matsue Y, Suzuki M, Nagahori W, Ohno M, Matsumura A, Hashimoto Y. \u03b2-blocker prevents sudden cardiac death in patients with hemodialysis. Int J Cardiol. 2013, 165:519-22. 10.1016\/j.ijcard.2011.09.037","journal-title":"Int J Cardiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali RK","year":"2011","unstructured":"Wali RK, Iyengar M, Beck GJ, et al.. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail. 2011, 4:18-26. 10.1161\/CIRCHEARTFAILURE.109.932558","journal-title":"Circ Heart Fail"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad F","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al.. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020, 396:819-29. 10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma A","year":"2023","unstructured":"Sharma A, Ferreira JP, Zannad F, et al.. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial. Eur J Heart Fail. 2023, 25:1337-48. 10.1002\/ejhf.2857","journal-title":"Eur J Heart Fail"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.672","article-title":"POS1323 SGLT2 inhibitors do not increase the risk of urinary tract infections regardless of immunosuppressive therapy: an active comparator new user design using a real-world hospital-based database in Japan","volume":"84","author":"Tsushima H","year":"2025","unstructured":"Tsushima H, Yajima N, Sakai R, Katagiri A, Tamura N. POS1323 SGLT2 inhibitors do not increase the risk of urinary tract infections regardless of immunosuppressive therapy: an active comparator new user design using a real-world hospital-based database in Japan. Ann Rheum Dis. 2025, 84:1362-3. 10.1016\/j.ard.2025.06.672","journal-title":"Ann Rheum Dis"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott C","year":"2020","unstructured":"Arnott C, Li Q, Kang A, et al.. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020, 9:e014908. 10.1161\/JAHA.119.014908","journal-title":"J Am Heart Assoc"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus BJ","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, et al.. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021, 99:750-62. 10.1016\/j.kint.2020.10.031","journal-title":"Kidney Int"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt B","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003, 348:1309-21. 10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir MR","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al.. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015, 372:211-21. 10.1056\/NEJMoa1410853","journal-title":"N Engl J Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart BA","year":"2012","unstructured":"Bart BA, Goldsmith SR, Lee KL, et al.. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012, 367:2296-304. 10.1056\/NEJMoa1210357","journal-title":"N Engl J Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens W","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, et al.. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022, 387:1185-95. 10.1056\/NEJMoa2203094","journal-title":"N Engl J Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg K","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al.. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010, 376:875-85. 10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor AL","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, et al.. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004, 351:2049-57. 10.1056\/NEJMoa042934","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt B","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014, 370:1383-92. 10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07161009","article-title":"Modeling the 4D study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes","volume":"5","author":"Chan KE","year":"2010","unstructured":"Chan KE, Thadhani R, Lazarus JM, Hakim RM. Modeling the 4D study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol. 2010, 5:856-66. 10.2215\/CJN.07161009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke H","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al.. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023, 147:296-309. 10.1161\/CIRCULATIONAHA.122.062779","journal-title":"Circulation"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney SD","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al.. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022, 146:1735-45. 10.1161\/CIRCULATIONAHA.121.054990","journal-title":"Circulation"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009, 361:2436-48. 10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015, 36:657-68. 10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski P","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al.. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020, 396:1895-904. 10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman B","year":"2018","unstructured":"Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, \u00d8rsted DD, Buse JB. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther. 2018, 9:2383-92. 10.1007\/s13300-018-0524-z","journal-title":"Diabetes Ther"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"The Digitalis Investigation Group","year":"1997","unstructured":"The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997, 336:525-33. 10.1056\/NEJM199702203360801","journal-title":"N Engl J Med"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivaf021","article-title":"Myocardial revascularization in patients with chronic kidney disease: a systematic review and meta-analysis of surgical versus percutaneous coronary revascularization","volume":"40","author":"Grazioli V","year":"2025","unstructured":"Grazioli V, Di Mauro M, Perocchio G, et al.. Myocardial revascularization in patients with chronic kidney disease: a systematic review and meta-analysis of surgical versus percutaneous coronary revascularization. Interdiscip Cardiovasc Thorac Surg. 2025, 40:ivaf021. 10.1093\/icvts\/ivaf021","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1122898","article-title":"Prevalence and global trends of polypharmacy in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"14","author":"Naseralallah L","year":"2023","unstructured":"Naseralallah L, Khatib M, Al-Khulaifi A, Danjuma M. Prevalence and global trends of polypharmacy in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2023, 14:1122898. 10.3389\/fphar.2023.1122898","journal-title":"Front Pharmacol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0001942021","article-title":"Less is more: deprescribing medications in older adults with kidney disease: a review","volume":"2","author":"Mohottige D","year":"2021","unstructured":"Mohottige D, Manley HJ, Hall RK. Less is more: deprescribing medications in older adults with kidney disease: a review. Kidney360. 2021, 2:1510-22. 10.34067\/KID.0001942021","journal-title":"Kidney360"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100819","article-title":"Deprescribing in dialysis: operationalizing \u201cless is more\u201d through a multimodal deprescribing intervention","volume":"6","author":"Vijayan M","year":"2024","unstructured":"Vijayan M, Mohottige D. Deprescribing in dialysis: operationalizing \u201cless is more\u201d through a multimodal deprescribing intervention. Kidney Med. 2024, 6:100819. 10.1016\/j.xkme.2024.100819","journal-title":"Kidney Med"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-023-00852-z","article-title":"Deprescribing in cardiometabolic conditions in older patients: a systematic review","volume":"45","author":"Hickman E","year":"2023","unstructured":"Hickman E, Seawoodharry M, Gillies C, Khunti K, Seidu S. Deprescribing in cardiometabolic conditions in older patients: a systematic review. Geroscience. 2023, 45:3491-512. 10.1007\/s11357-023-00852-z","journal-title":"Geroscience"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.0686","article-title":"SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors","volume":"185","author":"Wing S","year":"2025","unstructured":"Wing S, Ray JG, Yau K, et al.. SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors. JAMA Intern Med. 2025, 185:827-36. 10.1001\/jamainternmed.2025.0686","journal-title":"JAMA Intern Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02198-6","article-title":"Novel potassium binders in reduction of hyperkalemia and optimization of RAAS inhibitors treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis","volume":"85","author":"Huang N","year":"2025","unstructured":"Huang N, Xu Y, Liu C, et al.. Novel potassium binders in reduction of hyperkalemia and optimization of RAAS inhibitors treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis. Drugs. 2025, 85:1013-31. 10.1007\/s40265-025-02198-6","journal-title":"Drugs"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03254-z","article-title":"Renin-angiotensin-aldosterone system inhibitor dosing after initiation of outpatient sodium zirconium cyclosilicate therapy: the GALVANIZE RAASi real-world evidence study","volume":"42","author":"Agiro A","year":"2025","unstructured":"Agiro A, Greatsinger A, Mu F, et al.. Renin-angiotensin-aldosterone system inhibitor dosing after initiation of outpatient sodium zirconium cyclosilicate therapy: the GALVANIZE RAASi real-world evidence study. Adv Ther. 2025, 42:3960-77. 10.1007\/s12325-025-03254-z","journal-title":"Adv Ther"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-04026-x","article-title":"Prescription of ACE-Is\/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry","volume":"20","author":"Lido P","year":"2025","unstructured":"Lido P, Cantiero S, Galluccio A, et al.. Prescription of ACE-Is\/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry. Intern Emerg Med. 2025, 20:1787-801. 10.1007\/s11739-025-04026-x","journal-title":"Intern Emerg Med"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02218-8","article-title":"Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation","volume":"48","author":"Hashimoto N","year":"2025","unstructured":"Hashimoto N, Sakaguchi Y, Hattori K, et al.. Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation. Hypertens Res. 2025, 48:2034-44. 10.1038\/s41440-025-02218-8","journal-title":"Hypertens Res"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03228-1","article-title":"Guideline-recommended disease-modifying therapies for patients with cardiorenal disease: a call-to-action narrative review","volume":"42","author":"Wanner C","year":"2025","unstructured":"Wanner C, Zhao MH, Amin AN, et al.. Guideline-recommended disease-modifying therapies for patients with cardiorenal disease: a call-to-action narrative review. Adv Ther. 2025, 42:3141-57. 10.1007\/s12325-025-03228-1","journal-title":"Adv Ther"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87219","article-title":"Clinical effectiveness of sacubitril\/valsartan in heart failure patients with coexisting chronic kidney disease","volume":"17","author":"Batool M","year":"2025","unstructured":"Batool M, Javed Q, Shakeel A, Hameed S, Ikram W, Habib MK, Sajjad G. Clinical effectiveness of sacubitril\/valsartan in heart failure patients with coexisting chronic kidney disease. Cureus. 2025, 17:e87219. 10.7759\/cureus.87219","journal-title":"Cureus"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1177\/10742484241265337","article-title":"Comparison of the efficacy and safety of sacubitril\/valsartan and angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers in patients with reduced ejection fraction combined with moderate-to-severe chronic kidney disease","volume":"29","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Chen S, Xu X, Luo G, Huang J. Comparison of the efficacy and safety of sacubitril\/valsartan and angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers in patients with reduced ejection fraction combined with moderate-to-severe chronic kidney disease. J Cardiovasc Pharmacol Ther. 2024, 29:10.1177\/10742484241265337","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf224","article-title":"Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi\/ARB: a systematic review and meta-analysis","volume":"18","author":"Covic A","year":"2025","unstructured":"Covic A, Voroneanu L, Stefan AE, et al.. Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi\/ARB: a systematic review and meta-analysis. Clin Kidney J. 2025, 18:sfaf224. 10.1093\/ckj\/sfaf224","journal-title":"Clin Kidney J"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132190","article-title":"Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction","volume":"409","author":"Takeuchi S","year":"2024","unstructured":"Takeuchi S, Kohno T, Goda A, et al.. Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction. Int J Cardiol. 2024, 409:132190. 10.1016\/j.ijcard.2024.132190","journal-title":"Int J Cardiol"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155931","article-title":"DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman Y","year":"2024","unstructured":"Handelsman Y, Anderson JE, Bakris GL, et al.. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024, 159:155931. 10.1016\/j.metabol.2024.155931","journal-title":"Metabolism"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1159\/000541939","article-title":"Angiotensin receptor-neprilysin inhibitor for chronic kidney disease: strategies for renal protection","volume":"49","author":"Hishida E","year":"2024","unstructured":"Hishida E, Nagata D. Angiotensin receptor-neprilysin inhibitor for chronic kidney disease: strategies for renal protection. Kidney Blood Press Res. 2024, 49:916-32. 10.1159\/000541939","journal-title":"Kidney Blood Press Res"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2025.02.007","article-title":"Efficacy and safety of SGLT2 inhibitors in patients with heart failure according to kidney function: a systematic review and meta-analysis","volume":"78","author":"Hong D","year":"2025","unstructured":"Hong D, Hong M, Kim O, et al.. Efficacy and safety of SGLT2 inhibitors in patients with heart failure according to kidney function: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2025, 78:789-99. 10.1016\/j.rec.2025.02.007","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae003","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis","volume":"10","author":"Theodorakopoulou MP","year":"2024","unstructured":"Theodorakopoulou MP, Alexandrou ME, Tsitouridis A, et al.. Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024, 10:329-41. 10.1093\/ehjcvp\/pvae003","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal R","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJ, et al.. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025, 393:533-43. 10.1056\/NEJMoa2410659","journal-title":"N Engl J Med"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, et al.. Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022, 10:860-70. 10.1016\/j.jchf.2022.07.013","journal-title":"JACC Heart Fail"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF Trial","volume":"85","author":"Mc Causland FR","year":"2025","unstructured":"Mc Causland FR, Vaduganathan M, Claggett BL, et al.. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF Trial. J Am Coll Cardiol. 2025, 85:159-68. 10.1016\/j.jacc.2024.10.091","journal-title":"J Am Coll Cardiol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.2551","article-title":"Efficacy and tolerability of finerenone according to the use and dosage of diuretics: a prespecified analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura M","year":"2025","unstructured":"Chimura M, Jhund PS, Henderson AD, et al.. Efficacy and tolerability of finerenone according to the use and dosage of diuretics: a prespecified analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiol. 2025, 10:979-89. 10.1001\/jamacardio.2025.2551","journal-title":"JAMA Cardiol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal R","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021, 385:2507-19. 10.1056\/NEJMoa2110730","journal-title":"N Engl J Med"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062486","article-title":"Decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a prespecified analysis from the ADVOR trial","volume":"147","author":"Martens P","year":"2023","unstructured":"Martens P, Dauw J, Verbrugge FH, et al.. Decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a prespecified analysis from the ADVOR trial. Circulation. 2023, 147:201-11. 10.1161\/CIRCULATIONAHA.122.062486","journal-title":"Circulation"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20140212","article-title":"Meta-analysis of ultrafiltration versus diuretics treatment option for overload volume reduction in patients with acute decompensated heart failure","volume":"104","author":"Barkoudah E","year":"2015","unstructured":"Barkoudah E, Kodali S, Okoroh J, Sethi R, Hulten E, Suemoto C, Bittencourt MS. Meta-analysis of ultrafiltration versus diuretics treatment option for overload volume reduction in patients with acute decompensated heart failure. Arq Bras Cardiol. 2015, 104:417-25. 10.5935\/abc.20140212","journal-title":"Arq Bras Cardiol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors AA","year":"2014","unstructured":"Voors AA, van Veldhuisen DJ, Robertson M, et al.. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2014, 16:426-34. 10.1002\/ejhf.59","journal-title":"Eur J Heart Fail"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors AA","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E, et al.. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021, 23:1313-21. 10.1002\/ejhf.2221","journal-title":"Eur J Heart Fail"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4146863","article-title":"Efficacy of hydralazine-isosorbide-dinitrate and sodium-glucose cotransporter-2 inhibitors in reducing short-term readmission in African Americans with advanced heart failure","volume":"150","author":"Kluever M","year":"2024","unstructured":"Kluever M, Javeed M. Efficacy of hydralazine-isosorbide-dinitrate and sodium-glucose cotransporter-2 inhibitors in reducing short-term readmission in African Americans with advanced heart failure. Circulation. 2024, 150:10.1161\/circ.150.suppl_1.4146863","journal-title":"Circulation"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.03.032","article-title":"Hydralazine-isosorbide dinitrate use in patients with end-stage kidney disease on dialysis","volume":"7","author":"Mavrakanas TA","year":"2022","unstructured":"Mavrakanas TA, Soomro QH, Charytan DM. Hydralazine-isosorbide dinitrate use in patients with end-stage kidney disease on dialysis. Kidney Int Rep. 2022, 7:1332-40. 10.1016\/j.ekir.2022.03.032","journal-title":"Kidney Int Rep"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784.pub2","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer SC","year":"2014","unstructured":"Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014, CD007784. 10.1002\/14651858.CD007784.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kr\u00fcger N","year":"2025","unstructured":"Kr\u00fcger N, Schneeweiss S, Fuse K, et al.. Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction. JAMA. 2025, 334:1255-66. 10.1001\/jama.2025.14092","journal-title":"JAMA"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.23105","article-title":"Digoxin is still useful, but is still causing toxicity","volume":"91","author":"Crane AD","year":"2024","unstructured":"Crane AD, Militello M, Faulx MD. Digoxin is still useful, but is still causing toxicity. Cleve Clin J Med. 2024, 91:489-99. 10.3949\/ccjm.91a.23105","journal-title":"Cleve Clin J Med"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.12.009","article-title":"Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials","volume":"64","author":"Pun PH","year":"2014","unstructured":"Pun PH, Al-Khatib SM, Han JY, et al.. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014, 64:32-9. 10.1053\/j.ajkd.2013.12.009","journal-title":"Am J Kidney Dis"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000549","article-title":"Benefits and harms of coronary revascularization in non-dialysis-dependent chronic kidney disease and ischemic heart disease: a systematic review and meta-analysis","volume":"19","author":"Patel DM","year":"2024","unstructured":"Patel DM, Wilson LM, Wilson RF, Yang X, Gharibani T, Robinson KA. Benefits and harms of coronary revascularization in non-dialysis-dependent chronic kidney disease and ischemic heart disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2024, 19:1562-73. 10.2215\/CJN.0000000000000549","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2024.104945","article-title":"Long-term patient outcomes from a multidisciplinary cardiac rehabilitation programme with integrated nurse specialist support: a retrospective cohort study","volume":"161","author":"Marshall PW","year":"2025","unstructured":"Marshall PW, Benatar JR, Hennessy A, et al.. Long-term patient outcomes from a multidisciplinary cardiac rehabilitation programme with integrated nurse specialist support: a retrospective cohort study. Int J Nurs Stud. 2025, 161:104945. 10.1016\/j.ijnurstu.2024.104945","journal-title":"Int J Nurs Stud"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1097\/HCR.0000000000000781","article-title":"Benefits of cardiac rehabilitation in cardio-renal patients with heart failure with reduced ejection fraction","volume":"43","author":"Mrou\u00e9 A","year":"2023","unstructured":"Mrou\u00e9 A, Roueff S, Vanorio-Vega I, et al.. Benefits of cardiac rehabilitation in cardio-renal patients with heart failure with reduced ejection fraction. J Cardiopulm Rehabil Prev. 2023, 43:444-52. 10.1097\/HCR.0000000000000781","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.08.021","article-title":"Challenges to shared decision making about treatment of advanced CKD: a qualitative study of patients and clinicians","volume":"79","author":"House TR","year":"2022","unstructured":"House TR, Wightman A, Rosenberg AR, Sayre G, Abdel-Kader K, Wong SP. Challenges to shared decision making about treatment of advanced CKD: a qualitative study of patients and clinicians. Am J Kidney Dis. 2022, 79:657-66.e1. 10.1053\/j.ajkd.2021.08.021","journal-title":"Am J Kidney Dis"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01841-3","article-title":"Advance care planning for patients with end-stage kidney disease on dialysis: narrative review of the current evidence, and future considerations","volume":"37","author":"Adenwalla SF","year":"2024","unstructured":"Adenwalla SF, O'Halloran P, Faull C, Murtagh FE, Graham-Brown MP. Advance care planning for patients with end-stage kidney disease on dialysis: narrative review of the current evidence, and future considerations. J Nephrol. 2024, 37:547-60. 10.1007\/s40620-023-01841-3","journal-title":"J Nephrol"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14062102","article-title":"Mission and one-year experience of a kidney-heart outpatient service: a patient-centered management model","volume":"14","author":"Carollo C","year":"2025","unstructured":"Carollo C, Evola S, Sorce A, Cirafici E, Bennici M, Mul\u00e8 G, Geraci G. Mission and one-year experience of a kidney-heart outpatient service: a patient-centered management model. J Clin Med. 2025, 14:2102. 10.3390\/jcm14062102","journal-title":"J Clin Med"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1390729","article-title":"Machine learning model for cardiovascular disease prediction in patients with chronic kidney disease","volume":"15","author":"Zhu H","year":"2024","unstructured":"Zhu H, Qiao S, Zhao D, et al.. Machine learning model for cardiovascular disease prediction in patients with chronic kidney disease. Front Endocrinol (Lausanne). 2024, 15:1390729. 10.3389\/fendo.2024.1390729","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.03.007","article-title":"Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: a call for action","volume":"261","author":"Jefferies JL","year":"2023","unstructured":"Jefferies JL, Kovesdy CP, Ronco C. Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: a call for action. Am Heart J. 2023, 261:75-84. 10.1016\/j.ahj.2023.03.007","journal-title":"Am Heart J"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar A","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019, 380:1347-58. 10.1056\/NEJMra1814259","journal-title":"N Engl J Med"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.48550\/ARXIV.1705.07874","article-title":"A unified approach to interpreting model predictions. [PREPRINT]","author":"Lundberg S","year":"2017","unstructured":"Lundberg S, Lee SI. A unified approach to interpreting model predictions. [PREPRINT]. arXiv. 2017, 10.48550\/ARXIV.1705.07874","journal-title":"arXiv"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-39764-6_4","article-title":"Harnessing the digital revolution: a comprehensive review of mHealth applications for remote monitoring in transforming healthcare delivery","author":"Jat AS","year":"2023","unstructured":"Jat AS, Gr\u00f8nli TM. Harnessing the digital revolution: a comprehensive review of mHealth applications for remote monitoring in transforming healthcare delivery. Mobile Web and Intelligent Information Systems. MobiWIS 2023. Lecture Notes in Computer Science. Younas M, Awan I, Gr\u00f8nli TM (ed): Springer, Cham, Switzerland; 2023. 13977:55-67. 10.1007\/978-3-031-39764-6_4"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1485","article-title":"Remote patient monitoring using artificial intelligence: current state, applications, and challenges","volume":"13","author":"Shaik T","year":"2023","unstructured":"Shaik T, Tao X, Higgins N, Li L, Gururajan R, Zhou X, Acharya UR. Remote patient monitoring using artificial intelligence: current state, applications, and challenges. WIREs Data Min Knowl Discov. 2023, 13:e1485. 10.1002\/widm.1485","journal-title":"WIREs Data Min Knowl Discov"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1186\/s13677-025-00759-4","article-title":"Integration of wearable technology and artificial intelligence in digital health for remote patient care","volume":"14","author":"Ghadi YY","year":"2025","unstructured":"Ghadi YY, Shah SFA, Waheed W, Mazhar T, Ahmad W, Saeed MM, Hamam H. Integration of wearable technology and artificial intelligence in digital health for remote patient care. J Cloud Comput. 2025, 14:39. 10.1186\/s13677-025-00759-4","journal-title":"J Cloud Comput"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/23.022","article-title":"Benefits and challenges of remote patient monitoring as perceived by health care practitioners: a systematic review","volume":"27","author":"Serrano LP","year":"2023","unstructured":"Serrano LP, Maita KC, Avila FR, et al.. Benefits and challenges of remote patient monitoring as perceived by health care practitioners: a systematic review. Perm J. 2023, 27:100-11. 10.7812\/TPP\/23.022","journal-title":"Perm J"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson PB","year":"2014","unstructured":"Adamson PB, Abraham WT, Bourge RC, et al.. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014, 7:935-44. 10.1161\/CIRCHEARTFAILURE.113.001229","journal-title":"Circ Heart Fail"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321885","article-title":"Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis","volume":"109","author":"Curtain JP","year":"2023","unstructured":"Curtain JP, Lee MM, McMurray JJ, Gardner RS, Petrie MC, Jhund PS. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart. 2023, 109:823-31. 10.1136\/heartjnl-2022-321885","journal-title":"Heart"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.02.001","article-title":"Prognostic value of echocardiography for heart failure and death in adults with chronic kidney disease","volume":"248","author":"Fitzpatrick JK","year":"2022","unstructured":"Fitzpatrick JK, Ambrosy AP, Parikh RV, Tan TC, Bansal N, Go AS. Prognostic value of echocardiography for heart failure and death in adults with chronic kidney disease. Am Heart J. 2022, 248:84-96. 10.1016\/j.ahj.2022.02.001","journal-title":"Am Heart J"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2022.02.006","article-title":"Myocardial tissue imaging with cardiovascular magnetic resonance","volume":"80","author":"Nakamori S","year":"2022","unstructured":"Nakamori S, Dohi K. Myocardial tissue imaging with cardiovascular magnetic resonance. J Cardiol. 2022, 80:377-85. 10.1016\/j.jjcc.2022.02.006","journal-title":"J Cardiol"},{"key":"ref160","article-title":"Worsening renal function in acute decompensated heart failure: a bad sign, or maybe not?","volume":"130","author":"Bozkurt B","year":"2019","unstructured":"Bozkurt B, Kamat IS. Worsening renal function in acute decompensated heart failure: a bad sign, or maybe not?. Trans Am Clin Climatol Assoc. 2019, 130:41-50.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen SA","year":"2020","unstructured":"Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020, 180:223-30. 10.1001\/jamainternmed.2019.5284","journal-title":"JAMA Intern Med"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.48","article-title":"High-sensitivity assays for troponin in patients with cardiac disease","volume":"14","author":"Westermann D","year":"2017","unstructured":"Westermann D, Neumann JT, S\u00f6rensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017, 14:472-83. 10.1038\/nrcardio.2017.48","journal-title":"Nat Rev Cardiol"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.08.009","article-title":"Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction","volume":"13","author":"Neuen BL","year":"2025","unstructured":"Neuen BL, Vaduganathan M, Claggett BL, et al.. Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2025, 13:28-39. 10.1016\/j.jchf.2024.08.009","journal-title":"JACC Heart Fail"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/418935-the-intersection-of-heart-failure-and-chronic-kidney-disease-challenges-in-co-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:16:29Z","timestamp":1767791789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/418935-the-intersection-of-heart-failure-and-chronic-kidney-disease-challenges-in-co-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":165,"URL":"https:\/\/doi.org\/10.7759\/cureus.100993","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}